A phase IV study on the changes in ocular signs and symptoms in patients with ocular hypertension or open-angle glaucoma switched from Ganfort eye drops (bimatoprost 0.03%/timolol 0.5%) to Taptiqom eye drops (tafluprost 0.0015%/timolol 0.5%)

Trial Profile

A phase IV study on the changes in ocular signs and symptoms in patients with ocular hypertension or open-angle glaucoma switched from Ganfort eye drops (bimatoprost 0.03%/timolol 0.5%) to Taptiqom eye drops (tafluprost 0.0015%/timolol 0.5%)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 20 Sep 2016

At a glance

  • Drugs Tafluprost/timolol (Primary)
  • Indications Glaucoma; Ocular hypertension
  • Focus Therapeutic Use
  • Sponsors Santen Oy
  • Most Recent Events

    • 20 Sep 2016 This trial was completed in Finland (end date: 2016-05-25), according to European Clinical trials Database.
    • 30 Jun 2016 This trial is completed in Germany ( end date: 25 May 2016).
    • 25 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top